Opus Genetics’ (IRD) Market Outperform Rating Reaffirmed at Citizens Jmp

Posted by Brenda Bartman on Oct 16th, 2026

Opus Genetics (NASDAQ:IRD – Get Free Report)‘s stock had its “market outperform” rating reissued by equities researchers at Citizens Jmp in a research note issued on Friday, Benzinga reports. They presently have a $17.00 price objective on the stock. Citizens Jmp’s price target would suggest a potential upside of 342.71% from the company’s previous close.

A number of other research analysts have also recently weighed in on IRD. Wall Street Zen upgraded shares of Opus Genetics from a “sell” rating to a “hold” rating in a research note on Sunday, October 4th. TD Cowen initiated coverage on Opus Genetics in a research note on Wednesday, July 29th. They issued a “buy” rating for the company. JonesTrading raised their price target on Opus Genetics from $10.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, October 6th. Oppenheimer raised their price target on Opus Genetics from $10.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Finally, Chardan Capital restated a “buy” rating and issued a $16.00 price objective on shares of Opus Genetics in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Opus Genetics presently has an average rating of “Moderate Buy” and an average target price of $12.71.

Read Our Latest Stock Analysis on IRD

Opus Genetics Stock Performance

Shares of NASDAQ IRD traded down $0.21 during midday trading on Friday, hitting $3.84. 2,522,297 shares of the company’s stock traded hands, compared to its average volume of 1,434,492. The firm has a fifty day moving average of $4.50 and a 200 day moving average of $4.39. Opus Genetics has a 1 year low of $1.70 and a 1 year high of $7.07. The stock has a market capitalization of $317.38 million, a price-to-earnings ratio of -2.84 and a beta of 0.62.

Opus Genetics (NASDAQ:IRD – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.02. The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $2.63 million. On average, equities analysts anticipate that Opus Genetics will post -0.97 earnings per share for the current year.

Insider Activity

In related news, Director Fighting Blindness Foundation sold 556,000 shares of the company’s stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $4.96, for a total transaction of $2,757,760.00. Following the sale, the director owned 3,236,171 shares of the company’s stock, valued at $16,051,408.16. This represents a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Robert E. Gagnon sold 28,000 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $4.54, for a total transaction of $127,120.00. Following the transaction, the chief financial officer owned 556,375 shares of the company’s stock, valued at $2,525,942.50. This trade represents a 4.79% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 613,331 shares of company stock worth $2,971,509. 11.70% of the stock is currently owned by insiders.

Institutional Trading of Opus Genetics

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in shares of Opus Genetics during the 2nd quarter valued at about $12,809,000. Nantahala Capital Management LLC bought a new stake in Opus Genetics during the second quarter worth approximately $12,582,185. Trails Edge Capital Partners LP purchased a new stake in Opus Genetics during the second quarter valued at approximately $11,276,434. ADAR1 Capital Management LLC raised its position in Opus Genetics by 4,522.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,849,004 shares of the company’s stock valued at $8,413,000 after purchasing an additional 1,809,004 shares during the period. Finally, Opaleye Management Inc. lifted its stake in shares of Opus Genetics by 0.4% in the 2nd quarter. Opaleye Management Inc. now owns 1,125,000 shares of the company’s stock valued at $4,624,000 after purchasing an additional 5,000 shares during the last quarter. 14.97% of the stock is currently owned by institutional investors.

About Opus Genetics

(Get Free Report)

Opus Genetics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, a group of rare disorders that can cause progressive vision loss and blindness. The company’s research is centered on therapies intended to address the underlying genetic causes of these conditions rather than treating only their symptoms.

Opus Genetics is advancing an investigational pipeline of adeno-associated virus-based gene therapy candidates for diseases involving mutations in genes important to retinal function.